The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma
Launched by UNIVERSITY OF ALEPPO · Nov 28, 2023
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a medication called 5-fluorouracil (5-FU) to treat basal cell carcinoma (BCC), which is a common type of skin cancer. The researchers want to find out how safe and effective this treatment is for different types of BCC, specifically superficial and small nodular lesions. The trial will take place at Aleppo University Hospital and will involve patients who are between 5 and 90 years old. To be eligible, participants must have a superficial lesion or a nodular lesion smaller than 1.5 cm and must be willing to volunteer for the study.
Participants in this study can expect to receive 5-FU directly into their skin lesions. After the treatment, they will be monitored for 12 months to see how well the medication works and if there are any side effects. It’s important to note that patients with larger nodular lesions (greater than 1.5 cm) or ulcerated lesions cannot take part in this trial. The aim is to gather valuable information that can help improve treatment options for people with BCC.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 5 Years to 90 Years (Child, Adult, Older Adult).
- • Volunteer to participate in study
- • Superficial lesion
- • Nodular lesion (x ≤ 1.5 cm) patients are seen at the outpatient Department or in the dermatology wards at Aleppo University Hospital (AUH) over 12 months' period.
- Exclusion Criteria:
- • Ulcerative.
- • Nodular lesion (x ≥ 1.5 cm)
About University Of Aleppo
The University of Aleppo is a prestigious educational and research institution located in Aleppo, Syria, dedicated to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, the university leverages its extensive academic resources and expertise to conduct rigorous research aimed at improving patient outcomes and advancing healthcare practices. The institution is committed to upholding ethical standards and regulatory compliance in its clinical studies, fostering collaboration with national and international partners to contribute valuable insights to the medical community and enhance the overall quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aleppo, , Syrian Arab Republic
Patients applied
Trial Officials
Noura Abdulrahman, M.D.
Principal Investigator
Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria
Rama Haj mharram, M.D.
Study Director
Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria
Ahmad Yamen Arnaout, M.D.
Study Director
Faculty of Medicine, University of Aleppo, Aleppo, Syria.
Silva Ishkhanian, PhD
Study Director
Department of Dermatology and Venereology, Faculty of Medicine, University of Aleppo, Aleppo, Syria
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported